6001 International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial

✍ Scribed by Tebbutt, N.; Gebski, V.; Wilson, K.; Cummins, M.; Robinson, B.; Broad, A.; Cunningham, D.; Simes, J.; Stockler, M.; Price, T.

• Book ID: 123213439
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 49 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/S1359-6349(09)71096-1